Related references
Note: Only part of the references are listed.Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma
Timothy M. Nywening et al.
GUT (2018)
Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future
Adrian M. J. Pokorny et al.
INTERNAL MEDICINE JOURNAL (2018)
Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies
Aleksandra Adamska et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Gemcitabine-Related Pneumonitis in Pancreas Adenocarcinoma-An Infrequent Event: Elucidation of Risk Factors and Management Implications
Ibrahim Halil Sahin et al.
CLINICAL COLORECTAL CANCER (2016)
Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial
Timothy M. Nywening et al.
LANCET ONCOLOGY (2016)
Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies
Elena Gabriela Chiorean et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2015)
Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
Lola Rahib et al.
CANCER RESEARCH (2014)
Breaking immunotolerance of tumors: A new perspective for dendritic cell therapy
Jacek Rolinski et al.
JOURNAL OF IMMUNOTOXICOLOGY (2014)
Pancreatic Adenocarcinoma
David P. Ryan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Targeting Tumor-Infiltrating Macrophages Decreases Tumor-Initiating Cells, Relieves Immunosuppression, and Improves Chemotherapeutic Responses
Jonathan B. Mitchem et al.
CANCER RESEARCH (2013)
Tumor microenvironment profoundly modifies functional status of macrophages: Peritoneal and tumor-associated macrophages are two very different subpopulations
Dayron Rodriguez et al.
CELLULAR IMMUNOLOGY (2013)
Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 Axis
Dominic E. Sanford et al.
CLINICAL CANCER RESEARCH (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
Daniel D. Von Hoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity
Suzanne Ostrand-Rosenberg
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Myeloid-Derived Suppressor Cells Inhibit T-Cell Activation by Depleting Cystine and Cysteine
Minu K. Srivastava et al.
CANCER RESEARCH (2010)
Pancreatic Cancer
Manuel Hidalgo
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy
C. Marcela Diaz-Montero et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
Suzanne Ostrand-Rosenberg et al.
JOURNAL OF IMMUNOLOGY (2009)
Myeloid-derived suppressor cells as regulators of the immune system
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2009)
Mutant MCP-1 therapy inhibits tumor angiogenesis and growth of malignant melanoma in mice
Mitsuhisa Koga et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Cancer immunology - Cancer's bulwark against immune attack: MDS cells
Jean Marx
SCIENCE (2008)
Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma
Cecilia Melani et al.
CANCER RESEARCH (2007)
Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression
Stephanie K. Bunt et al.
CANCER RESEARCH (2007)
Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response
Pratima Sinha et al.
JOURNAL OF IMMUNOLOGY (2007)
CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers
Bo Huang et al.
CANCER LETTERS (2007)
Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host
B Huang et al.
CANCER RESEARCH (2006)
Expansion of myeloid immune suppressor Gr+CD11b+cells in tumor-bearing host directly promotes tumor angiogenesis
L Yang et al.
CANCER CELL (2004)
Share Paper
